PET imaging of focal demyelination and remyelination in a rat model of multiple sclerosis: comparison of [C-11]MeDAS, [C-11]CIC and [C-11]PIB

Show simple item record

dc.contributor Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.author FARIA, Daniele de Paula FMUSP-HC
COPRAY, Sjef
SIJBESMA, Jurgen W. A.
WILLEMSEN, Antoon T. M.
BUCHPIGUEL, Carlos A. FMUSP-HC
DIERCKX, Rudi A. J. O.
VRIES, Erik F. J. de
dc.date.issued 2014
dc.identifier.citation EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, v.41, n.5, p.995-1003, 2014
dc.identifier.issn 1619-7070
dc.identifier.uri http://observatorio.fm.usp.br/handle/OPI/7466
dc.description.abstract In this study, we compared the ability of [C-11]CIC, [C-11]MeDAS and [C-11]PIB to reveal temporal changes in myelin content in focal lesions in the lysolecithin rat model of multiple sclerosis. Pharmacokinetic modelling was performed to determine the best method to quantify tracer uptake. Sprague-Dawley rats were stereotactically injected with either 1 % lysolecithin or saline into the corpus callosum and striatum of the right brain hemisphere. Dynamic PET imaging with simultaneous arterial blood sampling was performed 7 days after saline injection (control group), 7 days after lysolecithin injection (demyelination group) and 4 weeks after lysolecithin injection (remyelination group). The kinetics of [C-11]CIC, [C-11]MeDAS and [C-11]PIB was best fitted by Logan graphical analysis, suggesting that tracer binding is reversible. Compartment modelling revealed that all tracers were fitted best with the reversible two-tissue compartment model. Tracer uptake and distribution volume in lesions were in agreement with myelin status. However, the slow kinetics and homogeneous brain uptake of [C-11]CIC make this tracer less suitable for in vivo PET imaging. [C-11]PIB showed good uptake in the white matter in the cerebrum, but [C-11]PIB uptake in the cerebellum was low, despite high myelin density in this region. [C-11]MeDAS distribution correlated well with myelin density in different brain regions. This study showed that PET imaging of demyelination and remyelination processes in focal lesions is feasible. Our comparison of three myelin tracers showed that [C-11]MeDAS has more favourable properties for quantitative PET imaging of demyelinated and remyelinated lesions throughout the CNS than [C-11]CIC and [C-11]PIB.
dc.description.sponsorship · Dutch MS Research Foundation [10-0700 MS]
· CAPES
dc.language.iso eng
dc.publisher SPRINGER
dc.relation.ispartof European Journal of Nuclear Medicine and Molecular Imaging
dc.rights restrictedAccess
dc.subject Demyelination; Remyelination; PET imaging; Myelin; Multiple sclerosis
dc.subject.other in-vivo quantification; pittsburgh compound-b; alzheimers-disease; lysophosphatidyl choline; white-matter; spinal-cord; myelin; injections; binding; repair
dc.title PET imaging of focal demyelination and remyelination in a rat model of multiple sclerosis: comparison of [C-11]MeDAS, [C-11]CIC and [C-11]PIB
dc.type article
dc.rights.holder Copyright SPRINGER
dc.description.group LIM/43
dc.identifier.doi 10.1007/s00259-013-2682-6
dc.identifier.pmid 24499866
dc.type.category original article
dc.type.version publishedVersion
hcfmusp.author FARIA, Daniele de Paula:HC:ICESP
hcfmusp.author BUCHPIGUEL, Carlos A.:FM:MDR
hcfmusp.author.external · COPRAY, Sjef:Univ Groningen, Univ Med Ctr Groningen, Dept Neurosci, NL-9713 AV Groningen, Netherlands
· SIJBESMA, Jurgen W. A.:Univ Groningen, Univ Med Ctr Groningen, Dept Nucl Med & Mol Imaging, NL-9713 AV Groningen, Netherlands
· WILLEMSEN, Antoon T. M.:Univ Groningen, Univ Med Ctr Groningen, Dept Nucl Med & Mol Imaging, NL-9713 AV Groningen, Netherlands
· DIERCKX, Rudi A. J. O.:Univ Groningen, Univ Med Ctr Groningen, Dept Nucl Med & Mol Imaging, NL-9713 AV Groningen, Netherlands
· VRIES, Erik F. J. de:Univ Groningen, Univ Med Ctr Groningen, Dept Nucl Med & Mol Imaging, NL-9713 AV Groningen, Netherlands
hcfmusp.origem.id 2-s2.0-84899084857
hcfmusp.origem.id WOS:000334417900022
hcfmusp.publisher.city NEW YORK
hcfmusp.publisher.country USA
hcfmusp.relation.reference · Compston A, 2008, LANCET, V372, P1502, DOI 10.1016/S0140-6736(08)61620-7
· Engler H, 2006, BRAIN, V129, P2856, DOI 10.1093/brain/awl178
· Fodero-Tavoletti MT, 2009, J NUCL MED, V50, P198, DOI 10.2967/jnumed.108.057984
· Franklin RJM, 2008, NAT REV NEUROSCI, V9, P839, DOI 10.1038/nrn2480
· HALL SM, 1972, J CELL SCI, V10, P535
· Klunk WE, 2004, ANN NEUROL, V55, P306, DOI 10.1002/ana.20009
· Lammertsma AA, 2007, COURS MAN PET PHARM, P65
· McDonald WI, 1999, PHILOS T ROY SOC B, V354, P1615, DOI 10.1098/rstb.1999.0506
· Pillipi M, 2011, RADIOLOGY, V259, P659
· Price JC, 2005, J CEREBR BLOOD F MET, V25, P1528, DOI 10.1038/sj.jcbfm.9600146
· Solbach C, 2005, APPL RADIAT ISOTOPES, V62, P591, DOI 10.1016/j.apradiso.2004.09.003
· Stankoff B, 2011, ANN NEUROL, V69, P673, DOI 10.1002/ana.22320
· Taveggia C, 2010, NAT REV NEUROL, V6, P276, DOI 10.1038/nrneurol.2010.37
· Wang YM, 2009, J NEUROSCI, V29, P14663, DOI 10.1523/JNEUROSCI.4082-08.2009
· WAXMAN SG, 1979, J NEUROL SCI, V44, P45, DOI 10.1016/0022-510X(79)90221-1
· Woodruff RH, 1999, GLIA, V25, P216, DOI 10.1002/(SICI)1098-1136(19990201)25:3<216::AID-GLIA2>3.0.CO;2-L
· Wu CY, 2013, ANN NEUROL, V74, P688, DOI 10.1002/ana.23965
· Wu CY, 2010, BIOORGAN MED CHEM, V18, P8592, DOI 10.1016/j.bmc.2010.10.018
· Wu CY, 2006, J HISTOCHEM CYTOCHEM, V54, P997, DOI 10.1369/jhc.5A6901.2006
dc.description.index MEDLINE
dc.identifier.eissn 1619-7089
hcfmusp.citation.scopus 23
hcfmusp.citation.wos 19
hcfmusp.affiliation.country Brasil
hcfmusp.affiliation.country Holanda


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace



Browse

My Account

Statistics